A detailed history of Carlyle Group Inc. transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 2,698,957 shares of RPHM stock, worth $4.53 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
2,698,957
Previous 2,698,957 -0.0%
Holding current value
$4.53 Million
Previous $4.08 Million 12.59%
% of portfolio
0.69%
Previous 0.49%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

BUY
$5.44 - $10.5 $3.4 Million - $6.56 Million
625,000 Added 30.14%
2,698,957 $17.7 Million
Q1 2023

May 05, 2023

BUY
$2.44 - $6.42 $5.06 Million - $13.3 Million
2,073,957 New
2,073,957 $12.4 Million

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Carlyle Group Inc. Portfolio

Follow Carlyle Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carlyle Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carlyle Group Inc. with notifications on news.